ArticleScientific reports2025
Machine learning fusion for glioma tumor detection.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Closing the loop on glioblastoma: A roadmap toward developing bioelectronics for continuous monitoring of tumor state.APL bioengineering · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The early detection of brain tumors is very important for treating them and improving the quality of life for patients. Through advanced imaging techniques, doctors can now make more informed decisions. This paper introduces a framework for a tumor detection system capable of grading gliomas. The system's implementation begins with the acquisition and analysis of brain magnetic resonance images. Key features indicative of tumors and gliomas are extracted and classified as independent components. A deep learning model is then employed to categorize these gliomas. The proposed model classifies gliomas into three primary categories: meningioma, pituitary, and glioma. Performance evaluation demonstrates a high level of accuracy (99.21%), specificity (98.3%), and sensitivity (97.83%). Further research and validation are essential to refine the system and ensure its clinical applicability. The development of accurate and efficient tumor detection systems holds significant promise for enhancing patient care and improving survival rates.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.